Johnson & Johnson (JNJ) Other Non-Current Liabilities (2009 - 2026)
Johnson & Johnson recorded quarterly Other Non-Current Liabilities of $486.0 million in Q1 2026, little changed quarter-over-quarter from $486.0 million in Q4 2025, and down 60.52% year-over-year from $1.2 billion in Q1 2025.
Johnson & Johnson's Other Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $486.0 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 60.52% year-over-year to $486.0 million; the TTM figure through Mar 2026 stood at $486.0 million (down 60.52% YoY), while the FY2025 annual figure was $486.0 million, down 60.07% from the prior year.
- Other Non-Current Liabilities came in at $486.0 million for Q1 2026 at Johnson & Johnson, roughly flat from $486.0 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $10.3 billion in Q2 2025 to a low of $486.0 million in Q2 2022.
- A 5-year average of $1.9 billion and a median of $1.1 billion in 2023 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities surged 722.36% in 2025 and plunged 60.52% in 2026, its largest moves.
- Johnson & Johnson's Other Non-Current Liabilities stood at $525.0 million in 2022, then soared by 108.0% to $1.1 billion in 2023, then advanced by 11.45% to $1.2 billion in 2024, then tumbled by 60.07% to $486.0 million in 2025, then changed by 0.0% to $486.0 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $486.0 million, $486.0 million, and $9.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 486.00 Mn |
| Dec 28, 2025 | 486.00 Mn |
| Sep 28, 2025 | 9.93 Bn |
| Jun 29, 2025 | 10.26 Bn |
| Mar 30, 2025 | 1.23 Bn |
| Dec 29, 2024 | 1.22 Bn |
| Sep 29, 2024 | 1.22 Bn |
| Jun 30, 2024 | 1.25 Bn |
| Mar 31, 2024 | 1.11 Bn |
| Dec 31, 2023 | 1.09 Bn |
| Oct 1, 2023 | 1.18 Bn |
| Jul 2, 2023 | 1.14 Bn |
| Apr 2, 2023 | 1.14 Bn |
| Jan 1, 2023 | 1.12 Bn |
| Oct 2, 2022 | 525.00 Mn |
| Jul 3, 2022 | 536.00 Mn |
| Apr 3, 2022 | 486.00 Mn |
| Jan 2, 2022 | 533.00 Mn |
| Oct 3, 2021 | 613.00 Mn |
| Jul 4, 2021 | 593.00 Mn |
| Apr 4, 2021 | 600.00 Mn |
| Jan 3, 2021 | 633.00 Mn |
| Sep 27, 2020 | 636.00 Mn |
| Jun 28, 2020 | 796.00 Mn |
| Mar 29, 2020 | 10.94 Bn |
| Dec 29, 2019 | 1.72 Bn |
| Sep 29, 2019 | 1.64 Bn |
| Jun 30, 2019 | 1.56 Bn |
| Mar 31, 2019 | 452.00 Mn |
| Dec 30, 2018 | 397.00 Mn |
| Sep 30, 2018 | 8.54 Bn |
| Jul 1, 2018 | 9.28 Bn |
| Apr 1, 2018 | 8.88 Bn |
| Dec 31, 2017 | 600.00 Mn |
| Oct 1, 2017 | 9.10 Bn |
| Jul 2, 2017 | 10.12 Bn |
| Apr 2, 2017 | 9.53 Bn |
| Jan 1, 2017 | 9.54 Bn |
| Oct 2, 2016 | 9.41 Bn |
| Jul 3, 2016 | 10.06 Bn |
| Apr 3, 2016 | 9.75 Bn |
| Jan 3, 2016 | 10.24 Bn |
| Sep 27, 2015 | 9.30 Bn |
| Jun 28, 2015 | 8.97 Bn |
| Mar 29, 2015 | 8.60 Bn |
| Dec 28, 2014 | 8.03 Bn |
| Sep 28, 2014 | 7.76 Bn |
| Jun 29, 2014 | 7.37 Bn |
| Mar 30, 2014 | 7.27 Bn |
| Dec 29, 2013 | 7.85 Bn |
| Sep 29, 2013 | 8.90 Bn |
| Jun 30, 2013 | 8.57 Bn |
| Mar 31, 2013 | 8.20 Bn |
| Dec 30, 2012 | 8.55 Bn |
| Sep 30, 2012 | 9.21 Bn |
| Jul 1, 2012 | 9.49 Bn |
| Apr 1, 2012 | 10.54 Bn |
| Jan 1, 2012 | 10.63 Bn |
| Oct 2, 2011 | 7.47 Bn |
| Jul 3, 2011 | 7.23 Bn |
| Apr 3, 2011 | 7.00 Bn |
| Jan 2, 2011 | 6.57 Bn |
| Oct 3, 2010 | 6.23 Bn |
| Jul 4, 2010 | 6.36 Bn |
| Apr 4, 2010 | 6.04 Bn |
| Jan 3, 2010 | 5.95 Bn |
| Sep 27, 2009 | 5.05 Bn |
| Jun 28, 2009 | 4.28 Bn |